CytomX Therapeutics, Inc. (CTMX)
- Previous Close
1.6800 - Open
1.6800 - Bid 1.6200 x 300
- Ask 1.7000 x 100
- Day's Range
1.6300 - 1.7000 - 52 Week Range
1.0400 - 2.8550 - Volume
118,529 - Avg. Volume
924,958 - Market Cap (intraday)
111.08M - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.90
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
www.cytomx.comRecent News: CTMX
Performance Overview: CTMX
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CTMX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CTMX
Valuation Measures
Market Cap
113.79M
Enterprise Value
-46.75M
Trailing P/E
--
Forward P/E
42.02
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.23
Price/Book (mrq)
--
Enterprise Value/Revenue
-0.46
Enterprise Value/EBITDA
10.85
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.56%
Return on Assets (ttm)
-1.75%
Return on Equity (ttm)
--
Revenue (ttm)
101.21M
Net Income Avi to Common (ttm)
-569k
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
174.51M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
43.66M